Phase 4CompletedAge-related condition
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (Industry)
- Enrollment
- 127 enrolled
- Conditions
- Parkinson's Disease; Motor Symptoms; Akinesia; Hypomobility; Delayed Levodopa Onset
- Interventions
- APOKYN; L-dopa; Trimethobenzamide
- Ages
- adults, older adults
- Registry
- NCT01770145
Full record on ClinicalTrials.gov
From the registry
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
Primary outcomes
- Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary.
History
Last registry update
Results first posted
Primary completion
Registered
Started